MHC class II as a therapeutic target in B-cell lymphomas: the CIITA road to paradise?
Diepstra
Arjan
A
Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, The Netherlands. a.diepstra@path.umcg.nl
D000970:Antineoplastic Agents / Q000627:therapeutic use; D018899:CpG Islands / Q000235:genetics; D019175:DNA Methylation / Q000187:drug effects; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D000949:Histocompatibility Antigens Class II / Q000235:genetics*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000235:genetics*; D009687:Nuclear Proteins / Q000235:genetics*; D011401:Promoter Regions, Genetic / Q000235:genetics*; D015534:Trans-Activators / Q000235:genetics*
D000970:Antineoplastic Agents; D000949:Histocompatibility Antigens Class II; C083728:MHC class II transactivator protein; D009687:Nuclear Proteins; D015534:Trans-Activators